Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757796

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757796

Multivalent Vaccines

PUBLISHED:
PAGES: 278 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Multivalent Vaccines Market to Reach US$15.7 Billion by 2030

The global market for Multivalent Vaccines estimated at US$9.4 Billion in the year 2024, is expected to reach US$15.7 Billion by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Conjugate Vaccine, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$9.9 Billion by the end of the analysis period. Growth in the Inactivated & Subunit Vaccine segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 14.4% CAGR

The Multivalent Vaccines market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 14.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Multivalent Vaccines Market - Key Trends & Drivers Summarized

Why Are Multivalent Vaccines a Strategic Priority in Immunization Programs?

Multivalent vaccines, which protect against multiple strains or species of pathogens in a single formulation, have become increasingly vital to global immunization strategies. Unlike monovalent vaccines that target a single antigen, multivalent formulations offer broad-spectrum protection, thereby reducing the number of injections, simplifying immunization schedules, and improving patient compliance. These vaccines are especially valuable in pediatric, travel, and outbreak-prone contexts where simultaneous protection against several diseases is critical for both individuals and communities.

The practical benefits of multivalent vaccines extend beyond convenience. They reduce logistical costs in vaccine storage, transport, and administration-especially in resource-constrained settings. Public health authorities prefer multivalent solutions for mass immunization campaigns, as they minimize contact points and optimize healthcare resource allocation. As new viral variants and co-infection threats emerge globally, the ability to confer multi-pathogen protection through a single dose is becoming a central objective in vaccine development and deployment.

What Technological Advancements Are Improving the Efficacy and Composition of Multivalent Vaccines?

Advances in molecular biology, adjuvant technology, and protein engineering are enabling the development of more stable, immunogenic, and broadly protective multivalent vaccines. Recombinant DNA platforms allow for the expression of multiple antigens in a single vector or carrier, improving manufacturing efficiency and antigen compatibility. Novel adjuvants such as saponins, toll-like receptor agonists, and lipid-based nanoparticles are being incorporated to enhance immune response while reducing reactogenicity.

Additionally, viral vector and mRNA platforms are being explored for their potential to encode multiple antigens in a single construct, as demonstrated during the COVID-19 vaccine race. Combination vaccines such as DTP (diphtheria-tetanus-pertussis), MMR (measles-mumps-rubella), and newer formulations like hexavalent infant vaccines are being continually refined to extend protection, improve tolerability, and support mixed immunization schedules. Cold chain optimization and thermostable vaccine formulations are also advancing multivalent vaccine usability in remote areas.

Which Diseases and Population Segments Are Driving Demand for Multivalent Vaccines?

Pediatric immunization remains the largest and most structured use case for multivalent vaccines, with infants receiving protection against up to six diseases in a single injection. Travel vaccines for diseases like typhoid, hepatitis A and B, and meningococcal infections are also frequently combined for global travelers. In seasonal and pandemic preparedness programs, multivalent influenza vaccines are designed annually to match circulating strains, providing broad protection in at-risk populations.

Elderly populations, immunocompromised individuals, and healthcare workers are key segments for new generation multivalent vaccines, especially as combination flu and COVID-19 booster candidates enter development. In veterinary medicine, multivalent vaccines are used extensively to protect livestock and pets against multiple viral and bacterial infections, helping reduce antimicrobial use and improve animal health outcomes. Emerging interest in combining respiratory syncytial virus (RSV), COVID-19, and influenza antigens is driving innovation in adult-targeted multivalent products.

The Growth in the Multivalent Vaccines Market Is Driven by Several Factors…

The growth in the multivalent vaccines market is driven by several factors including increasing demand for efficient immunization schedules, rising incidence of co-infections, and the need to enhance vaccine accessibility in resource-limited regions. Advancements in recombinant technology, adjuvant development, and vector-based platforms are enabling the design of more complex yet stable multivalent formulations. Supportive policies by global health organizations, growing investments in pediatric and adult vaccine programs, and the need to simplify logistics in pandemic scenarios are accelerating market adoption. As health systems aim to improve population coverage and respond to evolving pathogens, multivalent vaccines will remain at the forefront of global immunization strategies.

SCOPE OF STUDY:

The report analyzes the Multivalent Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Conjugate Vaccine, Inactivated & Subunit Vaccine, Live Attenuated Vaccine); Application (Pediatrics, Adults)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • BioNTech SE
  • Boehringer Ingelheim GmbH
  • CSL Seqirus
  • CureVac N.V.
  • Emergent BioSolutions Inc.
  • GC Biopharma Corp.
  • GlaxoSmithKline plc (GSK)
  • Indian Immunologicals Ltd.
  • LimmaTech Biologics AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • VBI Vaccines Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP35400

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Multivalent Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Broad-Spectrum Protection Against Infectious Diseases Fuels Development of Multivalent Vaccines
    • OEM Focus on Reducing Doses Per Immunization Cycle Supports Growth in Combined Antigen Formulations
    • Expansion of Pediatric and Routine Immunization Programs Strengthens Use of Multivalent Vaccine Platforms
    • Push for Universal Influenza and Coronavirus Vaccines Accelerates Multivalent Antigen Research
    • Increased Prevalence of Co-Infections Drives Innovation in Multi-Target Vaccine Technologies
    • OEM Development of mRNA-Based Multivalent Vaccines Enhances Speed and Flexibility in Pandemic Response
    • Regulatory Support for Single-Injection Immunization Models Promotes Approval of Combined Vaccine Candidates
    • Growth in Travel and Global Mobility Fuels Demand for Multivalent Protection in Endemic Regions
    • Rising Focus on Elderly and Immunocompromised Populations Strengthens Market for Broad-Protection Vaccines
    • Expansion of Veterinary Multivalent Vaccines Supports Disease Control in Animal Health and Zoonotic Risk
    • Integration of Nanoparticle Carriers and Lipid Formulations Improves Stability and Delivery of Multivalent Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multivalent Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Multivalent Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Conjugate Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Inactivated & Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Inactivated & Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Inactivated & Subunit Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Live Attenuated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • JAPAN
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • CHINA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • EUROPE
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Multivalent Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • FRANCE
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • GERMANY
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Multivalent Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • INDIA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Multivalent Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Multivalent Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • AFRICA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!